Literature DB >> 9108285

Control of Escherichia coli type 1 fimbrial gene expression in stationary phase: a negative role for RpoS.

S L Dove1, S G Smith, C J Dorman.   

Abstract

Expression of type 1 fimbriae in Escherichia coli is subject to phase-dependent control, with many regulatory inputs from proteins which organise or rearrange the structure of DNA. Inversion of a DNA segment carrying the promoter for expression of fimA, the gene encoding the fimbrial subunit protein, makes a key contribution to the switching of cells between fimbriate and afimbriate states. We have discovered that transcription of fimA is repressed as cells enter stationary phase. This repression is not seen in isogenic strains deficient in rpoS, the gene coding for the stationary phase-specific sigma factor RpoS. RpoS-deficient strains are also altered in the frequency of inversion of the fimA promoter segment. In the strains used in this study, inversion is catalysed by an integrase-like site-specific recombinase encoded by the fimB gene. We report that fimB transcription is repressed strongly as wild-type cells enter stationary phase but that this repression is alleviated in cells deficient in RpoS. These data suggest that RpoS has a negative regulatory role which may be indirect, at both the fimA and the fimB promoters.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108285     DOI: 10.1007/s004380050385

Source DB:  PubMed          Journal:  Mol Gen Genet        ISSN: 0026-8925


  18 in total

1.  Osmolarity and pH growth conditions regulate fim gene transcription and type 1 pilus expression in uropathogenic Escherichia coli.

Authors:  William R Schwan; Jeffrey L Lee; Farrah A Lenard; Brian T Matthews; Michael T Beck
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Stationary phase-like properties of the bacteriophage lambda Rex exclusion phenotype.

Authors:  R A Slavcev; S Hayes
Journal:  Mol Genet Genomics       Date:  2003-03-05       Impact factor: 3.291

3.  Genetic evidence that Legionella pneumophila RpoS modulates expression of the transmission phenotype in both the exponential phase and the stationary phase.

Authors:  Michael A Bachman; Michele S Swanson
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

4.  Microarray analysis of RpoS-mediated gene expression in Escherichia coli K-12.

Authors:  C L Patten; M G Kirchhof; M R Schertzberg; R A Morton; H E Schellhorn
Journal:  Mol Genet Genomics       Date:  2004-11-19       Impact factor: 3.291

5.  Negative regulation of mutS and mutH repair gene expression by the Hfq and RpoS global regulators of Escherichia coli K-12.

Authors:  H C Tsui; G Feng; M E Winkler
Journal:  J Bacteriol       Date:  1997-12       Impact factor: 3.490

6.  Comprehensive mutagenesis of the fimS promoter regulatory switch reveals novel regulation of type 1 pili in uropathogenic Escherichia coli.

Authors:  Huibin Zhang; Teodorus T Susanto; Yue Wan; Swaine L Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-30       Impact factor: 11.205

7.  rpoS mutations and loss of general stress resistance in Escherichia coli populations as a consequence of conflict between competing stress responses.

Authors:  Lucinda Notley-McRobb; Thea King; Thomas Ferenci
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

8.  IscR controls iron-dependent biofilm formation in Escherichia coli by regulating type I fimbria expression.

Authors:  Yun Wu; F Wayne Outten
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

9.  Oxygen-limiting conditions enrich for fimbriate cells of uropathogenic Proteus mirabilis and Escherichia coli.

Authors:  M Chelsea Lane; Xin Li; Melanie M Pearson; Amy N Simms; Harry L T Mobley
Journal:  J Bacteriol       Date:  2008-12-29       Impact factor: 3.490

10.  Type 1 fimbriae, a colonization factor of uropathogenic Escherichia coli, are controlled by the metabolic sensor CRP-cAMP.

Authors:  Claudia M Müller; Anna Aberg; Jurate Straseviçiene; Levente Emody; Bernt Eric Uhlin; Carlos Balsalobre
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.